Kiniksa Pharmaceuticals International, plc — Form 10-Q
Filed October 27, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Kinikska amended two product-specific agreements with Samsung Biologics Co., Ltd. for ARCALYST drug substance manufacturing. Amendment No. 1 (effective August 18, 2025) incorporated equipment investment terms into Exhibit C and updated scope of work in Exhibit D. Amendment No. 2 (effective September 22, 2026) increased Product Purchase Commitments for commercial product, raising annual manufacturing volumes for specified years by a total of [***] batches (specific figures redacted). Counterparties: Kinikska Pharmaceuticals (UK), Ltd. and Samsung Biologics Co., Ltd.
Why this rating
ARCALYST is core revenue product; volume increase positive operationally. However, financial terms redacted ([***]) prevent materiality assessment relative to ~$1.1B market cap. Routine contract amendment; insufficient disclosed detail to gauge business impact.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.